更新于：2024-09-26
Fosfomycin Sodium
磷霉素钠
更新于：2024-09-26
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C3H7Na2O4P |
InChIKeyXKMSQWKOGZTAQM-JSTPYPERSA-N |
CAS号26016-99-9 |
关联
48
项与 磷霉素钠 相关的临床试验COMPARISON OF NITROFURANTOIN WITH FOSFOMYCIN in TREATING CYSTITIS IN WOMEN
Therapeutic Strategies for Carbapenem-Resistant Acinetobacter Baumannii Infections: Study Protocol
Pharmacokinetics of a novel extended infusion regimen of fosfomycin
100 项与 磷霉素钠 相关的临床结果
登录后查看更多信息
100 项与 磷霉素钠 相关的转化医学
登录后查看更多信息
100 项与 磷霉素钠 相关的专利（医药）
登录后查看更多信息
4,473
项与 磷霉素钠 相关的文献（医药）2025-01-01Journal of Environmental Sciences
Metagenomic perspectives on antibiotic resistance genes in tap water: The environmental characteristic, potential mobility and health threat
Article
作者: He, Da ; Meng, Qiyue ; Zhang, Yibo ; Xia, Yu ; Fu, Jie ; Dang, Chenyuan
As an emerging environmental contaminant, antibiotic resistance genes (ARGs) in tap water have attracted great attention. Although studies have provided ARG profiles in tap water, research on their abundance levels, composition characteristics, and potential threat is still insufficient. Here, 9 household tap water samples were collected from the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) in China. Additionally, 75 sets of environmental sample data (9 types) were downloaded from the public database. Metagenomics was then performed to explore the differences in the abundance and composition of ARGs. 221 ARG subtypes consisting of 17 types were detected in tap water. Although the ARG abundance in tap water was not significantly different from that found in drinking water plants and reservoirs, their composition varied. In tap water samples, the three most abundant classes of resistance genes were multidrug, fosfomycin and MLS (macrolide-lincosamide-streptogramin) ARGs, and their corresponding subtypes ompR, fosX and macB were also the most abundant ARG subtypes. Regarding the potential mobility, vanS had the highest abundance on plasmids and viruses, but the absence of key genes rendered resistance to vancomycin ineffective. Generally, the majority of ARGs present in tap water were those that have not been assessed and are currently not listed as high-threat level ARG families based on the World Health Organization Guideline. Although the current potential threat to human health posed by ARGs in tap water is limited, with persistent transfer and accumulation, especially in pathogens, the potential danger to human health posed by ARGs should not be ignored.
2024-12-31Journal of medical economics
Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England
Article
作者: Kennedy, Nicholas ; Ahmed, Waqas ; Pollock, Richard F ; Dhar, Anjan ; Iqbal, Tariq H
AIMS:
Anemia is the most common extraintestinal complication of inflammatory bowel disease (IBD), with approximately half of cases caused by iron deficiency (ID). Intravenous iron is the preferred ID anemia (IDA) treatment where oral iron is contraindicated, ineffective or not tolerated, or where ID correction is urgent. The objective was to evaluate the cost-utility of ferric derisomaltose (FDI) versus ferric carboxymaltose (FCM) in patients with IBD and IDA in England, in whom IV iron treatment is preferred.
MATERIALS AND METHODS:
A patient-level simulation model was developed, capturing quality of life (QoL) differences based on SF-36v2 data from the PHOSPHARE-IBD randomized controlled trial, monitoring and incidence of post-infusion hypophosphatemia, and number of iron infusions required. Analyses were conducted over a five-year time horizon from the Department of Health and Social Care (DHSC) perspective, with healthcare provider and societal perspectives adopted in separate analyses. Future costs and effects were discounted at 3.5% per annum and one-way and probabilistic sensitivity analyses were performed.
RESULTS:
FDI increased quality-adjusted life expectancy by 0.075 QALYs versus FCM from 2.57 QALYs to 2.65 QALYs per patient. Patients receiving FDI required 1.63 fewer iron infusions over the five-year time horizon, driving infusion-related cost savings of GBP 496 per patient (GBP 2,188 versus GBP 1,692) from the DHSC perspective. Costs of monitoring and treating hypophosphatemia after FCM were GBP 226, yielding total savings of GBP 722 per patient (GBP 2,414 versus GBP 1,692) over the five-year time horizon. FDI also led to reduced costs versus FCM in the societal and provider analyses and was therefore the dominant intervention across all three perspectives.
LIMITATIONS:
The analysis did not capture patient adherence, hypophosphatemic osteomalacia, or fractures.
CONCLUSIONS:
Results showed that FDI improved patient QoL and reduced direct healthcare expenditure versus FCM in patients with IBD and IDA in England.
2024-12-31Future Science OA
Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis
Review
作者: Rehman, Faizan ur ; Fatima Zaidi, Syeda Mahrukh ; Zuhair, Varisha ; Rangwala, Burhanuddin Sohail ; Danish, Fnu ; Mussarat, Abdullah ; Shafique, Muhammad Ashir ; Mustafa, Muhammad Saqlain ; Khan, Aimen Waqar
Aim: Iron deficiency (ID) is associated with heart failure (HF) in a considerable proportion of patients. To improve the quality of life, lower the frequency of hospitalizations, and lower mortality rates of chronic HF patients (HF), this meta-analysis will look into the role of iron supplementation using ferric carboxymaltose (FCM). Methods & results: From inception until 1 October 2023, we conducted a thorough literature search of electronic databases for peer-reviewed publications. Around 5229 HF patients were included, of which 2691 received FCM while 2538 received placebo. Conclusion: FCM reduces HF-related hospitalizations but doesn't improve overall or cardiovascular mortality in those with HF and ID. The overall results support FCM's role in managing iron deficiency in heart failure.
100 项与 磷霉素钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 子宫旁组织炎 | 韩国 | 2024-09-09 | |
| 盆腔炎 | 韩国 | 2024-09-09 | |
| 脓毒症 | 韩国 | 2024-09-09 | |
| 菌血症 | 加拿大 | 2019-05-01 | |
| 复杂下尿路感染 | 加拿大 | 2019-05-01 | |
| 下呼吸道感染 | 加拿大 | 2019-05-01 | |
| 细菌性脑膜炎 | 加拿大 | 2019-05-01 | |
| 骨髓炎 | 加拿大 | 2019-05-01 | |
| 外耳炎 | 日本 | 1989-06-30 | |
| 中耳炎 | 日本 | 1989-06-30 | |
| 附件炎 | 日本 | 1985-01-28 | |
| 子宫内感染 | 日本 | 1985-01-28 | |
| 急性支气管炎 | 日本 | 1980-10-25 | |
| 膀胱炎 | 日本 | 1980-10-25 | |
| 脓胸 | 日本 | 1980-10-25 | |
| 出血性败血症 | 日本 | 1980-10-25 | |
| 肺脓肿 | 日本 | 1980-10-25 | |
| 腹膜炎 | 日本 | 1980-10-25 | |
| 肺炎 | 日本 | 1980-10-25 | |
| 肾盂肾炎 | 日本 | 1980-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 复杂的尿路感染 | 申请上市 | 爱尔兰 | 2022-01-30 | |
| 复杂腹腔感染 | 临床1期 | 爱尔兰 | 2022-01-30 | |
| 医院获得性肺炎 | 临床1期 | 爱尔兰 | 2022-01-30 | |
| 细菌性肺炎 | 临床1期 | 爱尔兰 | 2022-01-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 39 | 淵糧衊鹹糧窪餘衊構範(鬱網糧衊壓齋觸築網鑰) = 艱繭構夢衊繭齋網壓齋 願廠鹽獵醖範鑰製廠鏇 (餘衊願築淵構網窪鏇築, 鏇觸憲淵構願鹽構壓鏇 ~ 積築選衊壓淵繭衊製壓) 更多 | - | 2022-01-19 | |||
临床2/3期 | 465 | (ZTI-01) | 艱廠遞鑰鹽遞願襯網積(積網齋獵壓網繭廠遞齋) = 範襯醖蓋鬱衊艱網餘築 夢構網鏇夢築餘蓋選餘 (衊簾淵淵艱蓋憲鬱淵鹹, 構淵夢鹹夢簾構夢夢築 ~ 襯壓齋餘簾醖艱繭製積) 更多 | - | 2018-12-11 | ||
(Piperacillin Tazobactam) | 艱廠遞鑰鹽遞願襯網積(積網齋獵壓網繭廠遞齋) = 窪遞齋夢醖製鹽膚積獵 夢構網鏇夢築餘蓋選餘 (衊簾淵淵艱蓋憲鬱淵鹹, 鏇糧積築顧襯繭鏇選選 ~ 築窪積襯蓋壓選壓遞齋) 更多 | ||||||
N/A | 15 | Fosfomycin IV | 繭憲觸襯遞憲憲糧襯願(選膚築遞衊蓋網壓糧糧) = Only 1 had nausea 淵壓廠遞選積艱鑰膚願 (淵衊顧製築淵網網製憲 ) 更多 | - | 2018-09-15 | ||
N/A | - | 淵鹹淵膚積衊製醖鹹鹹(網鹽鹽網選衊壓鹽簾獵) = 範鏇簾襯積積構構餘蓋 餘製鑰衊鬱鏇蓋遞鏇淵 (艱獵鏇鑰壓窪蓋遞築繭 ) 更多 | - | 2015-11-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用